U.S. Machinery Stock News

Tandem Diabetes Care stock came into this earnings season on a tear, with the shares already sharply higher over the past month. Today the move turned into a jolt, as the stock jumped another 19% to US$22.38 after the Q2 print. The headline is clear: revenue reached US$254.56m and the company again reported a loss, yet investors locked on to one thing. The market is treating margin repair as the story that matters. Gross margin reached 57%, one of the highest levels Tandem Diabetes Care has...

The market cheered Real Brokerage with a 7.5% pop to US$2.14, yet the headline from this quarter is less about the share price and more about the profit squeeze behind it. Revenue reached US$700.6m, but Real still posted a net loss of US$8.0m for Q2. The company also reported an operating loss of US$7.0m that included US$11.6m of acquisition costs tied to the pending RE/MAX deal. For a stock often viewed as a high growth, low multiple brokerage platform, this gap between strong top line and...

AMN Healthcare Services just ripped 17% higher to about US$36, yet the headline from this quarter is not a clean growth story. Revenue landed at US$673.2m with adjusted EBITDA margin at 10.9%, helped by roughly US$27m of one time items that lifted reported profit and margins. The market is reacting to a sharp improvement from last year and a lower trailing P/E, while largely brushing past how much of this quarter’s strength came from non recurring boosts. The real question for you is how...

MBIA shares slipped about 3% to US$5.11 into the post earnings lull, yet the story the numbers tell is less about sudden collapse and more about a grinding balance sheet strain that refuses to clear. The market is reacting to another quarter of loss making results, with a Q2 GAAP net loss of US$46 million and book value per share still deeply negative. The question for investors is whether this selling reflects a sober read of MBIA’s ongoing capital and equity hole or a reflex move that...

The market reacted strongly to the Halozyme Therapeutics story today. Halozyme shares rose 20% to US$103.12 in regular trading, as traders moved to price in a biotech earnings report that appeared clean and solid rather than speculative. The catalyst was Q2 revenue of US$481m, supported by royalty revenue of US$308m and non-GAAP earnings per share of US$2.28. Management not only exceeded expectations but also raised full-year 2026 revenue and earnings guidance. This shift turned a strong...

WillScot Holdings stock fell 5.6% today, even though the company reported one of its cleanest quarters since last year’s hit to earnings. The market focused on the share price drop, while long term investors may focus on Q2 revenue of US$612.2m and adjusted EBITDA of US$228m with a 37.2% margin, plus a modest lift to full year guidance. Coming into this report, WillScot had already declined about 13% over the past three months. The headline this quarter is simple: profit quality improved,...

Fox Factory Holding entered this earnings report as a bruised story stock with modest recent gains, then jumped 12% to US$21.13 by the close. That kind of move suggests sentiment has shifted. The headline is simple: the company reported Q2 revenue of US$358.1m at the top of guidance and delivered about US$45.5m of adjusted earnings before interest, tax, depreciation and amortization, comfortably ahead of its own range. The market is treating that result as evidence the profit repair plan is...

Kenvue stock barely budged after earnings, inching up about 0.3% to US$19.23, yet the quarter quietly reinforced the core bullish argument. This is a branded consumer health business that many investors view as a steady earner, and the latest numbers again put earnings quality at the center of the story. Q2 basic earnings per share of roughly US$0.24 sat on top of a trailing twelve month earnings rise of about 17%, with net profit margin sitting near 11%. The headline is clear: earnings...

More than US$100b in tariff refunds is now on the table after the Supreme Court struck down IEEPA tariffs, and that kind of cash reshuffle can quietly reshape which large importers come out stronger. Investors watching liquidity, compliance strength and trade exposure may not want to sit this one out. This article walks through 3 large cap U.S. importers exposed to the ruling and how the news could matter for their stocks. The stocks below are just a starting sample, and the full screen...

CPI Card Group stock ripped 13% higher to US$27.72 after its Q2 report, a sharp move for a small payments manufacturer that had already logged strong gains in recent months. The emotional hook for traders is simple. Management raised full year revenue and free cash flow guidance after reporting record first half cash generation and higher gross margins helped by tariff refunds. The market is cheering the headline upgrades. The key question for you is whether that enthusiasm matches a quarter...

Ziff Davis stock jumped 5.7% to US$53.87 into the earnings close, which is a strong move for a company that is still reporting losses from continuing operations. The headline is not the loss. It is the sudden cash firepower created by the US$1.2b sale of the Connectivity business, paired with heavy share repurchases that have already cut the share count by about 11% this year. What you are seeing is a market trying to price a balance sheet and valuation story rather than a clean growth story...

Vistance Networks just jumped 8.3% to US$10.94 in the first full session after earnings, a sharp move for a stock that had been down over the past month and quarter. The headline is not growth at any cost. The story is a profit squeeze in a capital intensive telecom equipment business that needs healthy margins to fund its product roadmap. Q2 adjusted EBITDA for Vistance Networks’ continuing operations came in at US$36m on US$320m of net sales, while Aurora Networks’ EBITDA dropped much...

American Realty Investors shares edged 2.5% higher to US$15.36 after the Q2 release, even though the headline story was fresh pressure on profitability. The stock came into earnings after a weak 30 day stretch, and traders quickly focused on the company’s still positive trailing 12 month earnings. The real tension is between that profitable trailing picture and the quarterly income statement, which showed a small loss alongside modest revenue of US$12.9m. With a P/E of 29.7x, sitting above...

Advanced Drainage Systems dropped about 3% today, which looks odd when you line it up against what just happened in the business. The stock came into this earnings print after a flat month and a modest gain over the past quarter. Yet the company just booked roughly US$1.0b in quarterly revenue and one of its highest ever adjusted earnings before interest, tax, depreciation and amortization margins at 35.8%. The short term mood is cautious. The longer term story is that Advanced Drainage...

Novavax stock inched up about 3% to US$7.95 into the Q2 print, a modest move for a biotech that just posted another quarterly loss. The headline this quarter is not the loss itself. It is the pressure on the income statement as revenue for Q2 came in at US$56.7m and net loss reached US$53.4m. In the very short term traders are reacting to that mix of revenue and red ink. Long term holders are more likely focused on the gap between the current P/S multiple and valuation models that point to a...

Elevance Health stock has delivered a strong 36.9% return over the past year, and the current valuation checks now raise the question of whether that strength is still backed by a discount or already reflected in the price. Over the last 12 months, Elevance Health is up 36.9%, which puts recent buyers in a comfortable position and makes entry price more important for anyone considering the stock today. The company’s push to strengthen its connected cancer care model can support longer term...

Intellia Therapeutics stock jumped 6.2% to US$11.94 after earnings, which suggests investors heard something they liked from a gene editing story that has delivered sharp volatility in recent months. The headline is simple: the science stepped forward while the income statement stayed firmly in loss-making territory. Q2 revenue came in at US$7.7m and Intellia reported a net loss of US$106.6m. The cash pile of US$628.4m and management’s stated runway into at least 2028 now sit at the center of...

PRA Group stock jumped 9% to US$19.79 after the Q2 release, a sharp move for a consumer finance recovery specialist that has spent the past year in the red on a trailing basis. Traders reacted to one clear headline: core collections and balance sheet economics point to a rebuilding earnings engine, with Q2 net income of US$57.9m and basic earnings per share of US$1.52. The short term pop matters if you are trading the chart. The bigger story is whether this quarter marks the first credible...

Emergent BioSolutions came into this earnings print as a beaten down biotech, with the stock already down sharply over the past three months and now dropping another 8.9% to about US$4.84 after the release. The headline is not the top line. Q2 revenue of US$234.3m and adjusted EBITDA strength from its Medical Countermeasures business landed against a stark reality on the income statement. The company reported a Q2 net loss of US$180.2m, driven in large part by a large non cash impairment tied...

Red Cat Holdings stock jumped 6.2% to US$9.21 into the first full session after earnings, yet the mood around the stock is anything but relaxed. Traders are cheering the aerospace and defense drone specialist for one headline figure. Quarterly revenue landed at US$20.2m, with reported gross margin at 16.1%, which stands out in a sector where volume and unit economics can quickly swing sentiment. The catch is that Red Cat Holdings is still posting sizeable net losses and carries a rich P/S...

Verastem walked into this earnings print with a stock that had already been heating up, yet the market still punched the gas. Shares jumped about 14% to US$6.74 after the Q2 release. That kind of move in a volatile biotech usually signals investors see something more durable than a one quarter bump. The headline is clear for Verastem. Product revenue in Q2 reached about US$25.1m and total revenue for the quarter was a little over US$40m, while the company still reported a sizeable net loss...

ATI shareholders woke up to a 2% gain today, which looks modest compared with the strength of the latest aerospace heavy earnings print. The stock comes into this report already riding sharp momentum over the past quarter, yet the market reaction still feels restrained, given a headline quarter built on higher revenue of about US$1.3b and a clear jump in basic earnings per share. The real story is margin power. Adjusted EBITDA of US$284m and a 22.6% margin in Q2 turned ATI’s long running...

Tariff refunds worth an estimated $100b are now flowing back to giants like Apple, Ford and Amazon after the Supreme Court overturned parts of the Trump era trade policy. Some companies are signalling they will share at least some of the savings with shoppers. Others are keeping quiet. For investors, that mix of legal rulings, policy uncertainty and possible pricing shifts creates fresh openings. This article walks through 3 large cap consumer and retail stocks from the screener that stand...

The market shrugged off Liberty Live Holdings' latest quarter with a mild 0.9% slide, but the earnings story is far louder than that single day move suggests. This stock has been priced as a high growth entertainment play, yet Q2 still rested on heavy losses and a stretched valuation. Liberty Live reported Q2 revenue of US$147.1m alongside a net loss of US$268.7m, keeping earnings per share deep in the red. With a P/S multiple around 26x compared with much lower industry levels, the results...